Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 66 clinical trials
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (MECCA)

The study is designed to compare the clinical benefit following treatment with aromatase inhibitor in combination with metronomic capecitabine versus aromatase inhibitor alone in women with hormone receptor-positive, Her2-negative advanced breast cancer who have not received prior systemic anti-cancer therapies for their advanced/metastatic disease.

gonadotropin releasing hormone
erbb2
letrozole
anastrozole
HER2
  • 0 views
  • 30 Jan, 2022
  • 1 location
Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)

This is a single-arm, open-label study testing the effects of neoadjuvant therapy with the aromatase inhibitor letrozole in post-menopausal women with Stage I-III ER+, HER2- breast cancer. Eligible subjects will be treated with letrozole therapy for 4 to 12 weeks prior to surgical resection of the tumor. Tumor specimens obtained …

erbb2
hormone therapy
letrozole
invasive breast cancer
HER2
  • 0 views
  • 16 Nov, 2021
  • 2 locations
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis. The study hypothesis is that reducing adjuvant endocrine therapy from 5 to 2 years in a population with low risk …

  • 0 views
  • 27 Jan, 2021
  • 1 location
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (IPATHER)

This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors harboring PIK3CA mutations, candidates to receive maintenance HP after first line …

invasive breast cancer
breast cancer
immunological adjuvant
platelet count
PIK3CA
  • 2 views
  • 28 Feb, 2022
  • 3 locations
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer (DARE)

A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)

erbb2
progesterone
invasive breast cancer
immunohistochemistry
aromatase inhibitor
  • 0 views
  • 24 Mar, 2022
  • 15 locations
Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer

Treatment of hormone receptor (HR)-positive breast cancer with Aromatase Inhibitors (AIs) can lead to associated musculoskeletal pain and may cause patients to discontinue important treatment. This is a randomized controlled trial assessing the affect of Vitamin B12 on AI-associated joint pain and other outcomes. Participants will be randomly assigned 1:1 …

  • 0 views
  • 21 Apr, 2022
  • 1 location
Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer (IPT)

Cancer and depression commonly occur together, and each worsens the other. We conducted a large psychotherapy study treating depression in breast cancer patients, showing that psychotherapy lowers symptoms. Surprisingly, no studies have compared depression-focused psychotherapy to antidepressant medication for patients with breast cancer and depression. We applied to the National …

  • 0 views
  • 06 Apr, 2022
  • 1 location
Breast Cancer and Intrauterine Contraception

The present work seeks an alternative to the copper IUD for contraception in breast cancer patients, evaluating the satisfaction and continuity of the copper and silver IUD, as well as the quality of life, compared to the copper IUD, especially in the regarding the menstrual bleeding pattern of these patients …

carcinoma
intrauterine contraception
copper
cancer
breast carcinoma
  • 0 views
  • 16 Dec, 2021
  • 1 location
Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer (QUEST)

Based on proof-of-concept study, the investigators hypothesise that the QPOP prediction model can be further extended into use in solid tumors. Using breast cancer as a model, the investigators intend to investigate the feasibility of QPOP as a clinical decision support platform to identify patient-specific drug combinations across a range …

advanced breast cancer
  • 0 views
  • 16 Mar, 2022
  • 1 location
Hysteroscopic Findings in Ovarian Polycystic and Unexplained Infertile Women.

In many PCO infertile patients, abnormal endometrial echogenicity and thickness are documented by TVS and proved by endometrial biopsy in some cases. Should patients with normal appearance of the endometrium (echogenicity and thickness) by TVS require, endometrial biopsy remains controversial. Therefore, if hysteroscopic examination demonstrates the endometrial pattern (echogenicity, vascularity, …

hysteroscopy
prolactin
follicle stimulating hormone
cavities
  • 0 views
  • 14 Oct, 2021
  • 1 location